Procedure completed, awaiting publication in Official Journal
Role | Committee | Rapporteur | Shadows |
---|---|---|---|
Lead | CONT | HAYES Brian (EPP) | POCHE Miroslav (S&D), CZARNECKI Ryszard (ECR), DLABAJOVÁ Martina (ALDE), OMARJEE Younous (GUE/NGL), TARAND Indrek (Verts/ALE), VALLI Marco (EFD), KAPPEL Barbara (ENF) |
Opinion | ENVI | ||
Opinion | ITRE |
Activites
-
2018/04/18
Results of vote in Parliament
- Results of vote in Parliament
- Debate in Parliament
-
T8-0170/2018
summary
The European Parliament decided to grant discharge to the Director of the Innovative Medicines Initiative 2 (IMI 2) Joint Undertaking in respect of the implementation of the budget of the Joint Undertaking for the financial year 2016 and to approve the closure of the accounts of the joint venture for the same financial year. Noting that the Court of Auditors considered that the annual accounts of the Joint Undertaking for the financial year 2016 accurately reflect the financial position of the Joint Undertaking as at 31 December 2016, as well as the results of its operations, Parliament adopted 567 votes in favor, 121 against and 7 abstentions, a resolution containing a series of observations which form an integral part of the discharge decision: Financial management: the final 2016 budget available for the Seventh Framework Programme and Horizon 2020 programme implementation included commitment appropriations of EUR 307 053 000 and payment appropriations of EUR 263 423 000. The utilisation rates for commitment appropriations were 94.1 % (increase of 3.06 % compared to 2015). Members regretted to note that payment appropriations were for the third consecutive year below 75 %: in 2016 they were at 69.6 %. The Joint Undertaking is asked to improve the payment appropriations for the procedure next year. At the end of 2016, the in-kind and cash contributions of the industry members totalled EUR 506 million, compared to the Union’s cash contributions to the Seventh Framework Programme activities of the IMI Joint Undertaking, which amounted to EUR 728 million. Other observations: the resolution also contained a series of observations on the anti-fraud strategy, internal control systems and the prevention and management of conflicts of interests. It stressed the following points: in 2016 one instance of suspicion was communicated to OLAF which decided to dismiss the case based on the documentation provided. The Joint Undertaking undertook in parallel an independent financial audit which concluded with a minor adjustment and no significant material findings; at the end of 2016, the IMI 2 Joint Undertaking had only partially completed the integration of its control systems with the Commission’s common Horizon 2020 grant management and monitoring tools; the IMI 2 Joint Undertaking experienced some delays in payments to beneficiaries (universities, research organisations and small and medium-sized enterprises). The time-to-pay target of 90 days for interim payments was exceeded by 5 days in 2016. Corrective measures were taken by the IMI 2 Joint Undertaking to improve the situation, notably by enhancing cooperation with project consortia, by reviewing internal procedures and by hiring more staff for the financial unit. Lastly, the Commission was called on to ensure the direct involvement of the IMI 2 Joint Undertaking in the process of the Horizon 2020 mid-term review in the sphere of further simplifications and harmonisation of joint undertakings.
-
2018/03/22
Committee report tabled for plenary, single reading
-
A8-0075/2018
summary
The Committee on Budgetary Control adopted the report by Brian HAYES (EPP, IE) on discharge in respect of the implementation of the budget of the Innovative Medicines Initiative (IMI2) Joint Undertaking for the financial year 2016. The committee called on the European Parliament to grant the joint undertaking’s Executive Director discharge in respect of the implementation of the joint undertaking’s budget for the financial year 2016. Noting that the Court of Auditors issued a statement of assurance as to the reliability of the accounts and the legality and regularity of the underlying transactions for the financial year 2016, Members called on Parliament to approve the closure of the joint undertaking’s accounts. They made, however, a number of recommendations that need to be taken into account when the discharge is granted. They may be summarised as follows: Financial management: the final 2016 budget available for the Seventh Framework Programme and Horizon 2020 programme implementation included commitment appropriations of EUR 307 053 000 and payment appropriations of EUR 263 423 000. The utilisation rates for commitment appropriations were 94.1 % (increase of 3.06 % compared to 2015). Members regretted to note that payment appropriations were for the third consecutive year below 75 %: in 2016 they were at 69.6 %. The Joint Undertaking is asked to improve the payment appropriations for the procedure next year. Other observations: the report also contained a series of observations on the anti-fraud strategy, internal control systems and the prevention and management of conflicts of interests. Members regretted to discover that in 2016 one instance of suspicion was communicated to OLAF which decided to dismiss the case based on the documentation provided. The Joint Undertaking undertook in parallel an independent financial audit which concluded with a minor adjustment and no significant material findings. Members also regretted to note that the IMI 2 Joint Undertaking experienced some delays in payments to beneficiaries (universities, research organisations and small and medium-sized enterprises). The time-to-pay target of 90 days for interim payments was exceeded by 5 days in 2016. Corrective measures were taken by the IMI 2 Joint Undertaking to improve the situation, notably by enhancing cooperation with project consortia, by reviewing internal procedures and by hiring more staff for the financial unit. Lastly, the Commission is called on to ensure the direct involvement of the IMI 2 Joint Undertaking in the process of the Horizon 2020 mid-term review in the sphere of further simplifications and harmonisation of joint undertakings.
-
A8-0075/2018
summary
-
2018/03/20
Vote in committee, 1st reading/single reading
-
2017/09/13
Committee referral announced in Parliament, 1st reading/single reading
-
2017/06/26
Non-legislative basic document published
-
COM(2017)0365
summary
PURPOSE: presentation by the Commission of the consolidated annual accounts of the European Union for the financial year 2016, as part of the 2016 discharge procedure. Analysis of the accounts of the IMI 2 Joint Undertaking. CONTENT: the organisational governance of the EU consists of institutions, agencies and other EU bodies whose expenditure is included in the general budget of the Union. This Commission document concerns the EU's consolidated accounts for the year 2016 and details how spending by the EU institutions and bodies was carried out. The consolidated annual accounts of the EU provide financial information on the activities of the institutions, agencies and other bodies of the EU from an accrual accounting and budgetary perspective. It is the responsibility of the Commission's Accounting Officer to prepare the EU's consolidated annual accounts and ensure that they present fairly, in all material aspects, the financial position, the result of the operations and the cash flows of the EU institutions and bodies, including the IMI 2 JU, with a view to granting discharge. Discharge procedure: the final step of a budget lifecycle is the discharge of the budget for a given financial year. It represents the political aspect of the external control of budget implementation and is the decision by which the European Parliament, acting on a Council recommendation, "releases" the Commission (and other EU bodies) from its responsibility for management of a given budget by marking the end of that budget's existence. The European Parliament is the discharge authority within the EU. The discharge procedure may produce three outcomes: (i) the granting; (ii) postponement or; (iii) the refusal of the discharge. The final discharge report including specific recommendations to the Commission for action is adopted in plenary by the European Parliament and are subject to an annual follow up report in which the Commission outlines the concrete actions it has taken to implement the recommendations made. Each agency is subject to its own discharge procedure, including the IMI 2 JU. IMI 2 Joint Undertaking: the IMI 2 Joint undertaking, which is located in Brussels, was set up by Council Regulation (EU) No 557/2014, for a period up to 31 December 2024. The IMI 2 Joint Undertaking aims to increase clinical trial success rates of priority medicines identified by the World health Organization and where possible, reduce the time to reach clinical proof of concept in medicine development for certain diseases such as cancer and Alzheimer's disease. The socio-economic impacts of the first IMI projects to finish in 2016 confirms that the projects leverage funding and are delivering on IMI’s goal of helping to make concrete improvements to the medicines development process. As regards the JU’s accounts, these are presented in detail in the document published by the Joint Undertaking (please refer to the final accounts of the IMI 2 JU).
- DG {'url': 'http://ec.europa.eu/info/departments/budget_en', 'title': 'Budget'}, OETTINGER Günther
-
COM(2017)0365
summary
Documents
- Non-legislative basic document published: COM(2017)0365
- Committee report tabled for plenary, single reading: A8-0075/2018
- Results of vote in Parliament: Results of vote in Parliament
- Debate in Parliament: Debate in Parliament
- Decision by Parliament, 1st reading/single reading: T8-0170/2018
Amendments | Dossier |
9 |
2017/2184(DEC)
2018/03/01
CONT
9 amendments...
Amendment 1 #
Proposal for a decision 1 Paragraph 1 1.
Amendment 2 #
Motion for a resolution Paragraph 4 4. Regrets to note
Amendment 3 #
Motion for a resolution Paragraph 7 7. Notes with concern that out of the EUR 1 638 000 000 of Horizon 2020 funds allocated to the IMI Joint Undertaking, by the end of 2016 the IMI 2 Joint Undertaking had made commitments of EUR 515 000 000 (31 %) and payments of EUR 111 000 000 (7 % of the allocated funds) for the implementation of its first wave of projects;
Amendment 4 #
Motion for a resolution Paragraph 8 8. Notes that out of the EUR 1 638 000 000 of in-kind and cash contributions to be made by the industry members and associated partners to the activities of the IMI 2 Joint Undertaking,
Amendment 5 #
Motion for a resolution Paragraph 9 9. Notes that the IMI 2 Joint Undertaking has an anti-fraud strategy aligned with the common anti-fraud strategy of the Directorate-General for Research and Innovation; regrets to
Amendment 6 #
Motion for a resolution Paragraph 13 13. Regrets to note that at the end of 2016 – the third year of Horizon 2020 implementation – the IMI 2 Joint Undertaking had only partially completed the integration of its control systems with the Commission’s common Horizon 2020 grant management and monitoring tools ; and that prioritisation be given to complete the integration process quickly; acknowledges, however, the significant progress achieved in close cooperation with the Commission services which should enable all IMI 2 Joint Undertaking project reporting, monitoring and payment to be carried out via the common Horizon 2020 tools as of the beginning of 2018;
Amendment 7 #
Motion for a resolution Paragraph 13 13. Regrets to note that at the end of 2016 – the third year of Horizon 2020 implementation – the IMI 2 Joint Undertaking had only partially completed the integration of its control systems with the Commission’s common Horizon 2020 grant management and monitoring tools;
Amendment 8 #
Motion for a resolution Paragraph 14 14. Regrets to acknowledge that the IMI 2 Joint Undertaking experienced some delays in payments to beneficiaries (universities, research organisations and SMEs)
Amendment 9 #
Motion for a resolution Paragraph 15 a (new) 15 a. Calls on the Commission to ensure the direct involvement of the IMI 2 Joint Undertaking in the process of the Horizon 2020 mid-term review in the sphere of further simplifications and harmonisation of joint undertakings.
source: 618.281
|
History
(these mark the time of scraping, not the official date of the change)
activities |
|
commission |
|
committees/0 |
|
committees/0 |
|
committees/1 |
|
committees/1 |
|
committees/2 |
|
committees/2 |
|
docs |
|
events |
|
links |
|
other |
|
procedure/dossier_of_the_committee |
Old
CONT/8/10873New
|
procedure/final |
|
procedure/stage_reached |
Old
Procedure completed, awaiting publication in Official JournalNew
Procedure completed |
procedure/subject |
Old
New
|
activities/2 |
|
activities/3 |
|
activities/4 |
|
procedure/stage_reached |
Old
Awaiting committee decisionNew
Procedure completed, awaiting publication in Official Journal |
activities/0/docs/0/text |
|
activities/1/committees/0/shadows/1 |
|
committees/0/shadows/1 |
|
activities/1/committees/0/shadows/5 |
|
committees/0/shadows/5 |
|
activities/0/commission/0 |
|
other/0 |
|
activities/1/committees/0/date |
2017-09-20T00:00:00
|
activities/1/committees/0/rapporteur |
|
activities/1/committees/0/shadows |
|
committees/0/date |
2017-09-20T00:00:00
|
committees/0/rapporteur |
|
committees/0/shadows |
|
activities/1 |
|
procedure/dossier_of_the_committee |
CONT/8/10873
|
procedure/stage_reached |
Old
Preparatory phase in ParliamentNew
Awaiting committee decision |
activities |
|
committees |
|
links |
|
other |
|
procedure |
|